Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Transl Res. 2021 May 15;237:1–15. doi: 10.1016/j.trsl.2021.05.002

Figure 1. Proteasome inhibition increases levels of endogenous APOBEC3B.

Figure 1.

Immunoblotting was done for endogenous A3B in cells cultured in 6-well plates and treated overnight (18 hours) with proteasome inhibitors. Cells were lysed, and then protein amounts were normalized, denatured, and separated via electrophoresis. (A) H1299 and MCF7 cells were treated with a panel of proteasome inhibitors; MG132 (5 μM), Lactacystin (5 μM) and Epoxomicin (500 nM). (B) A3B protein (immunoblot in left panel and its quantitation in middle panel) and mRNA levels (relative to TBP, right panel) were measured by immunoblotting and RT-qPCR respectively from duplicate 6-well cultures of A549 lung cancer cells (n=3), (C) The same analyses were done for MCF7 breast cancer cells (n=3), and (D) HTB-41 head/neck cancer cells (n=4). For all panels, values are means ± SD error bars. For each cell line, protein level quantifications were normalized to the DMSO control for each replicate.